Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICOFIB: Nicotinamide in Hepatic Fibrosis
NCT06599918Phase 2Recruiting
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatic fibrosis comparing Nicotinamide with Placebo (2 arms). Primary endpoint: Effect of nicotinamide on hepatic fibrosis at 12 months. Started Apr 2024; status: recruiting.
02
Drugs
nicotinamide
03
Conditions
hepatic fibrosis
Beyond the preview
Go deeper on NCT06599918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06599918.